Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603018 · ClinicalTrials.gov registry record · NA
PET Imaging Study of Recovered Anorexics
A NA study of Anorexia Nervosa, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00603018: Completed NA study of Anorexia Nervosa, sponsored by University of Pittsburgh.
NCT00603018 is a NA study of Anorexia Nervosa that has completed, run by University of Pittsburgh. The registered enrollment target is 23 participants, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603018, a NA study of Anorexia Nervosa, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Several studies in the past suggest that individuals who have or had anorexia nervosa may have alterations in brain serotonin. Serotonin seems to play an important role in regulating anxiety, mood, and other symptoms found in anorexia nervosa. We will be using a technology called Positron Emission Tomography (PET), which is a method used to take pictures of the body, in this case, the brain. Study participants will undergo two baseline PET scans on the first day of the study. The women who have recovered from anorexia will then be given a medication called fluoxetine (also know as Prozac) to take for 8 weeks. At the end of the 8th week, they will return for a third PET scan. By comparing the brain scans, before and after fluoxetine treatment, we can understand more about how treatment with fluoxetine affects the serotonin receptors in the brain. We will be comparing brain serotonin system in women who have recovered from anorexia before and after medication in order to gain a better understanding of changes in the serotonin system associated with eating disorders. This study may help shed light on how to make fluoxetine a more effective treatment for anorexia nervosa.
Primary Outcome
We used PET and \[11C\]WAY to assess 5-HT1A binding potential (BP) = \[11C\]WAY 100635 BP = Distribution Volume (DV)ROI-DVcerebellum in striatal regions; subcortical regions including insula, medial temporal lobe, amygdala, hippocampus, midbrain, parahippocampal gyrus; and the neocortical regions (i.e., anterior cingulate cortex). Analysis of the PET data was performed using the Logan graphical method (Logan et al. 2001) with the cerebellum as a reference region for non-displaceable uptake. 23 R
Conditions Studied
Interventions
- DRUG Fluoxetine
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00603018 record still lists
NCT00603018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 950-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Anorexia Nervosa appearing as the primary indexed condition, and to 1 intervention - of which Fluoxetine is the first listed.
NCT00603018 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00603018 about?
NCT00603018 is a clinical study titled "PET Imaging Study of Recovered Anorexics". Several studies in the past suggest that individuals who have or had anorexia nervosa may have alterations in brain serotonin. Serotonin seems to play an important role in regulating anxiety, mood, and other symptoms found in anorexia nervosa. We will be using a technology called Positron Emission T...
What is the current status of trial NCT00603018?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2007-06. Estimated completion is 2008-12.
What conditions does trial NCT00603018 study?
This clinical trial studies the following conditions: Anorexia Nervosa.
What interventions are being tested in trial NCT00603018?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00603018?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00603018 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00603018's enrollment target sits among peer trials
23 33rd of 43 higher than 11 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Efficacy of Non-invasive Vagus Nerve Stimulation for Treatment of Low Weight Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia